Net sales for the quarter decreased by 2 percent to SEK 2,645 million (2,702). Adjusted for exchange rate effects, net sales increased by 2 percent, of which organic growth was 0.3 percent and acquired growth was 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy operations in the United Kingdom in December 2025, corresponding to SEK 63 million, and adjusted for this, organic growth amounted to 3 percent. Exchange rate effects had a negative impact on net sales of 4 percent in the quarter, corresponding to SEK 111 million.

EBITA in the quarter decreased by 3 percent to SEK 332 million (343) and the EBITA margin amounted to 12.5 percent (12.7). Exchange rate effects had a negative impact on EBITA of 4 percent, corresponding to SEK 13 million.

Net financial items amounted to SEK -46 million (-63) and profit after financial items totalled SEK 183 million (172). Net financial items primarily include interest expenses related to the financing of previous acquisitions as well as exchange rate effects. Interest expenses amounted to SEK 42 million (58) and exchange rate losses to SEK 2 million (1).

Profit after tax increased by 7 percent to SEK 128 million (120), and the effective tax rate was 30 percent (30). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses.